Results 161 to 170 of about 2,536 (255)

Prolonged ruxolitinib cream treatment for vitiligo among patients with no or limited response in the first 6 months

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Albert Wolkerstorfer, Melinda J. Gooderham, Michael Sebastian, David Rosmarin, Andrew Blauvelt, Maryam Shayesteh Alam, Jacek Zdybski, Shaoceng Wei, Deanna Kornacki, Thierry Passeron, John E. Harris   +10 more
wiley   +1 more source

Repurpose an FDA‐Approved Antibody Using DARPin‐Scaffolded Bridge Protein

Chemistry–Methods, Volume 6, Issue 5, May 2026.
The cell line and scalable upstream/downstream process development needed for every new monoclonal antibody are both highly expensive and time‐consuming, significantly increasing the cost of new antibody therapeutics. By contrast, the production of many synthetic binders can be accomplished rapidly and with lower production costs.
Michael Woolley, Joshua D. Bryant, Samuel Vrana, Karuppiah Chockalingam, Zhilei Chen   +4 more
wiley   +1 more source

Nanoparticulate protectants for the dry storage of protein therapeutics. [PDF]

Nanomedicine (Lond)
Park J, Resende MFR, Hudalla GA.
europepmc   +1 more source

Fianlimab, a human lymphocyte activation gene‐3 monoclonal antibody, in combination with cemiplimab: Tumor‐specific expansion cohorts in advanced malignancies

Cancer, Volume 132, Issue 9, 1 May 2026.
Abstract Background The dose escalation phase of a first‐in‐human (FIH) study demonstrated acceptable safety and preliminary antitumor activity of fianlimab (anti‐lymphocyte activation gene‐3 [LAG‐3]) as monotherapy and in combination with cemiplimab (anti‐programmed cell death‐1 [PD‐1]). Here, the authors present safety and clinical activity data from
Tae Min Kim, Stephen K. Williamson, Kyriakos P. Papadopoulos, Omid Hamid, Grace K. Dy, Ray McDermott, Ariel Birnbaum, John M. Kaczmar, Nehal Lakhani, Danny Rischin, Debashis Sarker, Afshin Dowlati, Xin‐Hua Zhu, Jyoti Malhotra, Jean‐Francois Pouliot, Jayakumar Mani, Laura Brennan, Fang Fang, Shuquan Chen, Mark Salvati, Israel Lowy, Ahmed Khaled, Karl D. Lewis, Glenn Kroog, Matthew G. Fury, Byoung Chul Cho   +25 more
wiley   +1 more source

Triplex viability PCR for simultaneous quantification of <i>Lactobacillus acidophilus</i>, <i>Streptococcus thermophilus</i>, and <i>Bifidobacterium bifidum</i> in live microbial formulations. [PDF]

Front Microbiol
Del Pio L, Catone S, Pisani G, Franciosa G.   +3 more
europepmc   +1 more source

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

Transfusion, EarlyView.
Thane Kubik, Theodros Mamo, David H. McKenna   +2 more
wiley   +1 more source

Gut Dysbiosis as a Shared Mechanism in Obesity and Hypertension: Exploring a Promising Therapeutic Avenue

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
This review synthesises current knowledge on gut microbiome involvement in obesity and hypertension, evaluates microbiome‐based therapeutic strategies, and identifies critical research gaps to guide future investigations aimed at mitigating the dual pandemics.
Andrej Belančić, Almir Fajkić, Yusuf Ziya Sener, Ana Jelaković, Lejla Alić, Elvira Meni Maria Gkrinia, Donatella Verbanac, Bojan Jelaković   +7 more
wiley   +1 more source

Chemistry, manufacturing, and controls for live microbial products: addressing classification challenges and enhancing process validation. [PDF]

Front Microbiomes
Slijkerman R, van Dijk R, Mohieddin N, Ciarlante I, de Jong A, Schuler MM.   +5 more
europepmc   +1 more source

Five‐year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non‐small‐cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE‐042 China study

International Journal of Cancer, Volume 158, Issue 9, Page 2429-2439, 1 May 2026.
What's new? Global research has found that for people newly diagnosed with advanced non‐small cell lung cancer (NSCLC), the anti‐PD‐1 monoclonal antibody pembrolizumab on its own often leads to better results than traditional chemotherapy. The present report details long‐term findings of pembrolizumab therapy specifically among Chinese patients.
Yi‐Long Wu, Li Zhang, Yun Fan, JianYing Zhou, Li Zhang, Qing Zhou, Wei Li, ChengPing Hu, GongYan Chen, Xin Zhang, CaiCun Zhou, Carmen González Arenas, Zhenghong Chen, Wen Cheng Yu, Tony S. K. Mok   +14 more
wiley   +1 more source

Not quite a cure yet: unlocking the unfulfilled promise of live biotherapeutics for disease treatment. [PDF]

Front Pharmacol
Verdugo-Meza A, Chiang HM, Mayer EA, Gibson DL.   +3 more
europepmc   +1 more source